Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

The University of Alabama at Birmingham

Status

Completed

Conditions

Renal Disease

Sickle Cell Disease

Glomerular Disease

Treatments

Diagnostic Test: iohexol GFR

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT04380610

IRB-300005433

1R01HL153386

Details and patient eligibility

About

The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients

Full description

200 pediatric and 200 adult SCA participants will undergo mGFR using iohexol at baseline and at one year. On the same day, participants will undergo clinical and laboratory variables important for developing an eGFR equation. From baseline data, the investigators will perform a training and validation cohort of biologically relevant predictor variables to develop a novel equation. Then the investigators will compare the novel SCA eGFR equation to the established eGFR equation. From one year data, the investigators will determine the longitudinal concordance between pediatric and adult novel and standard eGFR equations with mGFR and variables that may alter longitudinal inferences.

In a subset of 30 adult participants, the investigators will also evaluate the correlation between mGFR using iohexol and a novel measure of mGFR that is more time efficient

Enrollment

120 patients

Sex

All

Ages

5 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

SCA patients (HbSS and SB0 thalassemia)
Age: 5.0-50.0 at enrollment

Exclusion criteria

Recent SCA complication associated with hospitalization (within 30 days) or ED visit (within 14 days)
Current AKI defined as >0.3mg/g increase in SCr from prior visit
Known history of anaphylaxis with contrast agent or known pregnancy